Sanofi SA

SNW2

Company Profile

  • Business description

    Sanofi develops and markets drugs with a concentration in vaccines, immunology, oncology, cardiovascular disease, diabetes, and over-the-counter treatments. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing about 30% of total sales, but profits are shared with Regeneron. Just over 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.

  • Contact

    46, Avenue de la Great Army
    Paris75017
    FRA

    T: +33 153774000

    E: [email protected]

    https://www.sanofi.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Drug Manufacturers - General

    Fiscal Year End

    31 December 2025

    Employees

    82,878

Stocks News & Analysis

stocks

Our view of BHP after June quarter results

Record copper volumes are reported.
stocks

James Hardie transfers of share listing to New York Stock Exchange

The change is a result of the controversial Azek acquisition.
stocks

The 10 best US dividend stocks

These are the top dividend-paying stocks to buy in 2025.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,916.3090.50-1.00%
CAC 407,822.670.670.01%
DAX 4024,289.5181.42-0.33%
Dow JONES (US)44,342.19142.30-0.32%
FTSE 1008,992.1219.480.22%
HKSE24,895.2069.540.28%
NASDAQ20,895.6510.010.05%
Nikkei 22539,819.1182.08-0.21%
NZX 50 Index12,943.9763.570.49%
S&P 5006,296.790.57-0.01%
S&P/ASX 2008,659.4097.80-1.12%
SSE Composite Index3,549.8915.410.44%

Market Movers